238 related articles for article (PubMed ID: 26860465)
1. Tumor slice culture system to assess drug response of primary breast cancer.
Naipal KA; Verkaik NS; Sánchez H; van Deurzen CH; den Bakker MA; Hoeijmakers JH; Kanaar R; Vreeswijk MP; Jager A; van Gent DC
BMC Cancer; 2016 Feb; 16():78. PubMed ID: 26860465
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
3. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
Hoffman RM; Tanino H
Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer--response rates to chemotherapeutic agents studied in vitro.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(4):3405-11. PubMed ID: 12926081
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Mehta RS; Bornstein R; Yu IR; Parker RJ; McLaren CE; Nguyen KP; Li KT; Fruehauf JP
Breast Cancer Res Treat; 2001 Apr; 66(3):225-37. PubMed ID: 11510694
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
9. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
10. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
Liedtke C; Wang J; Tordai A; Symmans WF; Hortobagyi GN; Kiesel L; Hess K; Baggerly KA; Coombes KR; Pusztai L
Breast Cancer Res Treat; 2010 Jun; 121(2):301-9. PubMed ID: 19603265
[TBL] [Abstract][Full Text] [Related]
12. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
15. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
Salter KH; Acharya CR; Walters KS; Redman R; Anguiano A; Garman KS; Anders CK; Mukherjee S; Dressman HK; Barry WT; Marcom KP; Olson J; Nevins JR; Potti A
PLoS One; 2008 Apr; 3(4):e1908. PubMed ID: 18382681
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
[No Abstract] [Full Text] [Related]
17. Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.
Leiva MC; Garre E; Gustafsson A; Svanström A; Bogestål Y; Håkansson J; Ståhlberg A; Landberg G
J Cell Physiol; 2021 Jun; 236(6):4709-4724. PubMed ID: 33368325
[TBL] [Abstract][Full Text] [Related]
18. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Rivera E; Holmes FA; Buzdar AU; Asmar L; Kau SW; Fraschini G; Walters R; Theriault RL; Hortobagyi GN
Breast J; 2002; 8(1):2-9. PubMed ID: 11856154
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity.
Cree IA; Kurbacher CM; Untch M; Sutherland LA; Hunter EM; Subedi AM; James EA; Dewar JA; Preece PE; Andreotti PE; Bruckner HW
Anticancer Drugs; 1996 Aug; 7(6):630-5. PubMed ID: 8913430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
